Accelerating Meaningful Progress in Fibrosis
Mediar’s approach offers a critical window to tackle later-stage fibrosis, which is among the hardest-to-treat conditions with little to no available therapeutic options. We are currently advancing first-in-class antibodies to address fibrosis in several fibrotic indications including those in lung and liver. Our foundational and robust science supports future expansion opportunities into other indications, which could include renal and cardiac fibrosis.
Our Pipeline
- Target
- Clinical Candidate
- Discovery
- Preclinical
- IND-enabling
- Phase 1/2
WNT1-inducible signaling pathway protein-1 (WISP-1) is a secreted matricellular protein shown to have a relevant role in fibrosis progression, making the protein a compelling target for anti-fibrosis therapeutics. MTX-463 is a first-in-class human IgG1 antibody designed to neutralize the WISP-1-mediated fibrotic signaling that spans several fibrotic indications, including those in the lung and liver. Initiation of Phase 1 clinical studies for this program is anticipated in H1-2024.
Ephrin ligands and Eph receptors mediate biological processes involved in tissue fibrosis including cell migration, myofibroblast activation, and tissue remodeling. A growing body of evidence has implicated EphrinB2 in the fibrosis of the lungs, liver and heart. Expression of EphrinB2 and its receptors may also play a role in defining the fibrotic niche. MTX-474 is a first-in-class human IgG1 antibody designed to neutralize the EphrinB2 signaling that causes the onset and progression of fibrosis. Initiation of Phase 1 clinical studies for this program is anticipated in H2-2024.